Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants.
We report the phase III trial efficacy of 7-valent pneumococcal conjugate vaccine against clinical and culture proven otitis media (OM) among Navajo and White Mountain Apache infants. Efficacy was -0.4% (95% CI: -19.4 to 15.6) for clinically-diagnosed OM, 5.1% (95% CI: -51.5 to 40.6) for severe OM, and 64% (95% CI: -34% to 90%) for vaccine serotype pneumococcal OM suggesting that this vaccine is efficacious for pneumococcal OM in this high risk population.
O'Brien
Katherine L
KL
Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. klobrien@jhsph.edu
David
Angeline B
AB
Chandran
Aruna
A
Moulton
Lawrence H
LH
Reid
Raymond
R
Weatherholtz
Robert
R
Santosham
Mathuram
M
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007198:Indians, North American; D007223:Infant; D022401:Meningococcal Vaccines / Q000276:immunology* / Q000627:therapeutic use; D010033:Otitis Media / Q000276:immunology / Q000628:therapy*; D011008:Pneumococcal Infections / Q000276:immunology* / Q000628:therapy*; D022242:Pneumococcal Vaccines / Q000276:immunology* / Q000627:therapeutic use; D014481:United States
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines